Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma

SHANGHAI and Hong Kong, Nov. 18, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the China National Medical Products Administration (NMPA) has approved a single-arm dose-finding Phase I/II study designed to evaluate the safety of selinexor (ATG-010) in combination with the R2 regimen of lenalidomide plus rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) and relapsed/refractory indolent non-Hodgkin lymphoma (rriNHL) (the "SWATCH" study). NHL is one of the most prevalent hematologic malignancies in China and in the world. In 2016, China reported 68,500 newly diagnosed NHL cases and 37,600 NHL-related deaths, which accounted for 14.9% and 15.7% of the NHL incidences and deaths reported globally. The age-standardized incidence rate, mortality rate, and prevalence of NHL in China are 4.29, 2.45, and 14.9 per 100,000, respectively, and both incidence and mortality rates have been on the rise with the increase in age. Although rituximab in combination with various chemotherapies can deliver significant improvement to the overall survival (OS) of patients with NHL, rriNHL represent an urgent unmet need. Further, while there have been promising advances in rrDLBCL treatment, effective treatment remains a challenge. Ruijin Hospital of Shanghai Jiaotong University School of Medicine is the lead site in China for this 10-center study. The first segment of study will enroll patients with rrDLBCL in a dose-escalation phase, the second subsequent dose-expansion phase will enroll patients with either rrDLBCL (arm A) or rriNHL (arm B). Enrolled patients will be treated with selinexor in combination with the R2 regimen of lenalidomide plus rituximab (SR2). The objective of the Phase I/II study is to determine the treatment dose of the SR2 regimen, and evaluate the safety, tolerability, and preliminary efficacy of the combination regimen in patients with rrDLBCL or rriNHL who are not eligible for high-dose chemotherapy (HDC) or autologous stem cell transplantation (ASCT). Prof. Weili Zhao, Chief Physician of the Hematology Department, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Vice Chair of the Chinese Society of Hematology, Vice Chair of the Lymphoma Alliance of the Chinese Society of Clinical Oncology, and the principal investigator of the study, commented: "With the current standard of care treatments, some patients with DLBCL or iNHL would still eventually relapse or become refractory, thus face a dismal prognosis. Therefore, we urgently need new therapies with novel mechanisms and fresh combination strategies that can bring this patient population greater survival benefits. This is the breakthrough we clinicians have been hoping for. Selinexor monotherapy has already been approved by the U.S. FDA for the treatment of rrDLBCL. In this Phase I/II study, we will evaluate the safety and tolerability of selinexor in combination with the R2 regimen in patients with rrDLBCL or rriNHL ineligible for DHC/ASCT. We hope the SR2 regimen will offer a more effective treatment option to patients with rrNHL." Dr. Jay Mei, Founder, Chairman and CEO of Antengene, noted: "We are pleased that the NMPA has approved the single-arm dose-finding Phase I/II study designed to assess the safety and efficacy of selinexor plus the R2 regimen for the treatment of rrDLBCL and rriNHL. Selinexor (ATG-010) is Antengene's first commercial-stage program. This study highlight's Antengene's complementary approach of developing new regimen and the Company's dedication to select diseases, such as rriNHL, an indication for which selinexor was already approved by the U.S. FDA but still represents an urgent unmet clinical need in the APAC region. We look forward to advancing this study under the supervision of the NMPA, in an effort to develop a safe and effective new treatment regimen for patients with rrDLBCL and rriNHL."

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!